Will Expectations for Another Earnings Beat Recast Align Technology's (ALGN) Digital Dental Growth Narrative?
Align Technology (ALGN) is set to release its Q1 2026 earnings on April 29, with analysts optimistic due to previous revenue growth, earnings beats, and strategic focus on digital dental solutions. While the company's long-term investment narrative hinges on the adoption of clear aligners and digital workflows, competitive pricing and potential margin pressure remain short-term risks. Investors are watching for signs of demand strengthening or softening, particularly in high-value aligner and scanner sales, which will influence perceptions of future earnings beats and the company's financial outlook.
Allspring Global Investments Boosts Stake in Insight Enterprises
Allspring Global Investments Holdings LLC significantly increased its stake in Insight Enterprises, Inc. by 31.5% in the fourth quarter of 2025, now owning 250,509 shares valued at $21 million. This move signals the investment management firm's confidence in Insight Enterprises, a major provider of IT hardware, software, and services, highlighting its strong position in the technology services sector. The investment firm is now one of the largest institutional investors in Insight Enterprises, which it views as a bellwether for the broader technology sector.
Sight Sciences wins $34M patent ruling against Alcon
Sight Sciences has won a $34 million patent infringement lawsuit against Alcon. The ruling was issued by a federal jury in Delaware regarding certain glaucoma surgical devices. This legal victory is significant for Sight Sciences in the medical device industry.
Why Align Technology (ALGN) is poised to beat earnings estimates again
This article from Zacks Equity Research suggests that Align Technology (ALGN) is likely to beat its upcoming earnings estimates. The analysis is based on a strong earnings ESP and a favorable Zacks Rank, which have historically indicated a high probability of an earnings beat for the company.
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell shares are falling, what you need to know
This article indicates that shares of Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell are currently experiencing a decline. The title suggests that the content would provide an explanation for these drops, but the article text itself is not provided.
Dental Equipment & Technology Stocks Q4 Recap: Benchmarking Align Technology (NASDAQ:ALGN)
This article reviews the Q4 performance of several dental equipment and technology stocks, highlighting Align Technology (NASDAQ:ALGN), Envista (NYSE:NVST), Dentsply Sirona (NASDAQ:XRAY), and Henry Schein (NASDAQ:HSIC). While the sector collectively saw a strong Q4 with revenues beating estimates, share prices have averaged a slight decline. The piece also briefly touches on broader market concerns shifting from AI disruption to geopolitical risks in early 2026.
Align Technology Inc. stock underperforms Thursday when compared to competitors
Align Technology Inc. (ALGN) stock declined by 1.23% to $170.60 on Thursday, breaking a two-day winning streak. This underperformance occurred during a mixed trading session where the S&P 500 Index rose, but the Dow Jones Industrial Average fell. The article provides a brief overview of the stock's performance relative to major market indices.
Dental Equipment & Technology Stocks Q4 Recap: Benchmarking Align Technology (NASDAQ:ALGN)
This article provides a Q4 recap of dental equipment and technology stocks, focusing on companies like Align Technology (ALGN), Envista Holdings (NVST), Dentsply Sirona (XRAY), and Henry Schein (HSIC). It details their revenue performance against analyst expectations, highlighting Envista as the strongest performer and Align Technology showing the weakest performance against estimates, despite a stock price increase. The piece also touches on industry trends, including innovation and challenges like economic uncertainty and regulatory pressures.
Align sets April 29 earnings release, 4:30 p.m. investor call
Align Technology, Inc. (Nasdaq: ALGN) is scheduled to release its first-quarter 2026 financial results on Wednesday, April 29, 2026, after market close. The company will also host a conference call and audio webcast at 4:30 p.m. ET to discuss these results. Investors can access the financial release and webcast details on Align's Investor Relations website.
Align Technology to Announce First Quarter 2026 Results on April 29, 2026
Align Technology, Inc. (Nasdaq: ALGN) announced it will report its first quarter 2026 financial results on Wednesday, April 29, 2026, after the close of market. The results will be released at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET to discuss the financial performance. Details will be available on the Investor Relations section of Align's website.
Align Technology to Announce First Quarter 2026 Results on April 29, 2026
Align Technology (Nasdaq: ALGN) is set to announce its first quarter 2026 financial results on Wednesday, April 29, 2026, after market close. The results will be released at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET to discuss the financial performance. The medical device company specializes in the Invisalign System, iTero intraoral scanners, and exocad CAD/CAM software.
Align Technology Inc (ALGN) Trading 2.89% Higher on Apr 1
Align Technology Inc (ALGN) shares rose by 2.89% on April 1st, reaching an intraday high of $178.17 and closing at $176.38. Wall Street analysts have an average one-year price target of $203.84 for ALGN, suggesting a 15.57% upside, while GuruFocus estimates a fair value of $263.34, implying a 49.3% upside. The company currently holds an "Outperform" recommendation from brokerage firms.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
DENTSPLY SIRONA (XRAY) is positioned for growth due to new digital-implant workflows and increased investment in research and development, despite facing headwinds from forex fluctuations and soft European demand. The company plans double-digit increases in R&D, expands its dealer network, and implements cost restructuring to reallocate funds toward debt reduction and share repurchases. However, near-term revenue decline, margin pressure from tariffs, and weakness in core segments like implants and orthodontics remain concerns for the company.
Align Technology Inc Stock: Invisalign Leader Faces Evolving Orthodontics Market in 2026
Align Technology Inc., known for its Invisalign clear aligners, holds a dominant position in the digital orthodontics market. The company's success is driven by its direct-to-consumer model, proprietary software, and global expansion, particularly in North America. While facing competition and macroeconomic headwinds, Align continues to innovate with AI-enhanced simulations and international growth strategies.
Align Technology Inc Stock: Invisalign Leader Faces Evolving Orthodontics Market in 2026
Align Technology Inc, known for its Invisalign clear aligners, holds a strong position in the digital orthodontics market. The company's business model leverages precision manufacturing and digital services, primarily through Invisalign sales and the iTero scanner ecosystem. While facing competition from 3D printing startups and traditional braces, Align sustains its market lead through intellectual property, partnerships, and an innovation pipeline, with analysts holding a consensus "hold" rating due to balanced growth prospects and valuation concerns.
North America Clear Aligners and Retainers Market Is Going
This report provides a comprehensive analysis of the North America Clear Aligners and Retainers Market, covering trends, growth drivers, challenges, and opportunities from 2026-2033. It includes competitor analysis featuring companies like Align Technology Inc. and 3M Company, market segmentation, and details on research methodologies. The report aims to help market participants make informed strategic decisions and forecast future profitability.
Align Technology Inc. stock underperforms Friday when compared to competitors
Align Technology Inc. (ALGN) experienced a decline in stock value on Friday, underperforming both its industry competitors and the broader market. The stock fell by 1.63%, closing at $289.47, while the S&P 500 saw a slight increase. This downturn adds to a challenging period for Align Technology, which has lost significantly over the last year.
Align Technology to Announce First Quarter 2026 Results on April 29, 2026
Align Technology, Inc. (Nasdaq: ALGN) will report its first quarter 2026 financial results on Wednesday, April 29, 2026, after the market closes. The company will release results at 4:00 p.m. ET (1:00 p.m. PT) and host a conference call to discuss them at 4:30 p.m. ET (1:30 p.m. PT). Align Technology is a leading global medical device company known for its Invisalign System, iTero intraoral scanners, and exocad CAD/CAM software.
Factors Supporting the Continued Inclusion of DENTSPLY SIRONA Shares in Your Investment Portfolio
Dentsply Sirona (XRAY) is positioned for growth due to its innovative digital implant solutions and increased R&D investments, despite facing challenges like unfavorable currency exchange rates and weak European demand. The company is expanding dealer partnerships and optimizing costs for long-term benefits, but short-term revenue pressures and margin compression are expected in 2026. While analysts project a revenue decrease and lower EPS for 2026, the article suggests it's a hold with potential for future improvement.
Wealth Enhancement Advisory Services LLC Boosts Stake in Align Technology, Inc. $ALGN
Wealth Enhancement Advisory Services LLC significantly increased its stake in Align Technology (ALGN) by 63% in Q4 2025, now holding 25,343 shares worth $4.282 million. This move is part of a broader trend of institutional investors raising their holdings, bringing total institutional ownership to 88.43%. Despite an EVP insider selling shares, the company beat Q4 earnings and revenue estimates, and analysts maintain a "Moderate Buy" consensus rating with a $198.08 price target.
Wealth Firm Boosts Stake in Align Technology
Wealth Enhancement Advisory Services has increased its stake in Align Technology, a leading producer of clear dental aligners and intraoral scanners. The firm acquired an additional 9,792 shares, bringing its total holding to 25,343 shares valued at $4,282,000, reflecting confidence in the digital dentistry market's growth potential. This move highlights the growing recognition of Align Technology's importance in advancing dental care through technology.
Polianta Ltd Buys Shares of 10,400 Align Technology, Inc. $ALGN
Polianta Ltd has acquired 10,400 shares of Align Technology (ALGN) valued at approximately $1.623 million, making it their 24th largest portfolio position. This comes as Align Technology reported strong quarterly earnings, beating analyst expectations with EPS of $3.29 and revenue of $1.05 billion. Despite some insider selling, institutional investors hold a significant portion of the company's stock, and analysts maintain a "Moderate Buy" rating with an average target price of $198.08.
Align Technology Inc (ALGN) Stock Price Down 6.17% on Mar 30
Shares of Align Technology Inc (ALGN) dropped 6.17% on March 30, closing at $166.38. This places ALGN 20.13% below its 52-week high and 36.38% above its 52-week low. Wall Street analysts have an average target price of $203.84, suggesting a 22.51% upside, while GuruFocus estimates a fair value of $262.36, indicating a 57.69% upside.
Blackstone closes new $6.3B life sciences fund, its largest yet
Blackstone has successfully closed its latest life sciences fund, raising $6.3 billion, making it their largest life sciences fund to date. The group, based in Cambridge, MA, has been actively investing in the Boston area economy, evidenced by deals with companies like Alnylam and Moderna. Nick Galakatos, who leads Blackstone's life sciences business, recently joined the board of BioMed Realty, another Blackstone-owned entity.
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
Sight Sciences has secured a significant legal victory against Alcon, receiving an order on post-trial motions that upholds a jury's verdict of willful patent infringement. The court awarded Sight Sciences over $34 million in past damages, plus supplemental damages and interest, and a 10% ongoing royalty on Hydrus® Microstent revenue through November 2028. This ruling recognizes the strength of Sight Sciences' intellectual property in interventional glaucoma and aims to protect their investments in innovative eyecare technologies.
Align Technology, Inc. (NASDAQ:ALGN) Sees Significant Increase in Short Interest
Align Technology (NASDAQ:ALGN) experienced a 25.5% increase in short interest during March, reaching 2,964,353 shares, which represents about 4.2% of its total shares sold short. The company maintains a "Moderate Buy" consensus rating from analysts with an average target price of $198.08, despite an EVP selling a notable portion of his shares.
Bausch + Lomb Corp Stock: Eye Health Leader with Strong Product Portfolio and Growth Potential for Investors
Bausch + Lomb Corp (ISIN: CA07174N1090) is a major player in the vision care industry, offering a wide range of products including contact lenses, surgical equipment, and pharmaceuticals. The company leverages its long heritage, global distribution, and continuous innovation in lens technology and drug delivery to maintain a competitive edge. With an aging global population and rising demand for eye health solutions, Bausch + Lomb presents a defensive healthcare investment opportunity with growth potential for North American investors, despite risks related to supply chain, currency fluctuations, and regulatory hurdles.
Align Technology Shares Purchased by Hunter Perkins Capital
Hunter Perkins Capital Management LLC significantly increased its stake in Align Technology, Inc. (NASDAQ:ALGN) during the fourth quarter of 2025, now owning 43,842 shares. This 383.1% increase suggests strong confidence in the medical equipment provider's growth potential, particularly with its Invisalign clear aligner system. The investment firm's increased holding now represents 0.06% of Align Technology's outstanding shares.
Is Align Technology (ALGN) Pricing Reflect Its Recovery Story In Clear Aligners And Digital Dentistry
This article analyzes Align Technology's (ALGN) stock valuation using Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratios. The DCF model suggests the stock is undervalued by 22.9%, with an intrinsic value of $215.87 per share. However, its P/E ratio of 28.90x is slightly above the industry average, indicating it might be overvalued based on this metric given its Fair Ratio of 26.08x.
Flexible registration options campaign fails to lift Align Technology stock after 6.17% slide
Align Technology (ALGN) stock slid 6.17% despite a promotion for flexible registration options, indicating significant short- and medium-term selling pressure. The stock trades below key moving averages with negative momentum signals, and while long-term support exists, the forecast for the upcoming week suggests a continued decline is more likely than an upside. Investors are advised to monitor the company's innovation momentum following recent advancements in its digital dentistry portfolio.
Align Technology's Strategic Pivot: Efficiency and Global Expansion in Focus
Align Technology is focusing on international growth and aggressive cost-saving targets as it approaches a pivotal spring season. The company's Q1 2026 report will assess the effectiveness of new efficiency programs and overseas expansion, with a goal to improve corporate margins by 100 basis points through cost reductions and productivity enhancements. While North America stabilizes, the primary growth engines are identified as Europe and the Asia-Pacific region, which are considered underpenetrated markets.
Align Technology (LTS:0HCK) NonCurrent Deferred Revenue : $0 Mil (As of Dec. 2025)
This article reports that Align Technology's (LTS:0HCK) NonCurrent Deferred Revenue was $0 million as of December 2025. GuruFocus rates the stock with a GF Score of 85/100 and considers it significantly undervalued, with a GF Value of $249.03 against a current price of $165.77. The company, known for its Invisalign products and iTero scanners, has five warning signs that investors should review.
SG Americas Securities Boosts Stake in Align Technology
SG Americas Securities LLC has significantly increased its stake in Align Technology (NASDAQ:ALGN) by over 183% during the fourth quarter, adding 89,628 shares to its holdings. This move suggests the institutional investor sees substantial growth potential in the company, a major player in dental and orthodontic technology. The increase reflects broader market confidence in Align Technology's future performance, as other institutional investors have also boosted their stakes.
The Bull Case For Align Technology (ALGN) Could Change Following FTSE All-World Index Removal – Learn Why
Align Technology (ALGN) was removed from the FTSE All-World Index in March 2026, which could impact institutional investor holdings and the company's liquidity. While the exclusion is technical, it intersects with current pressures on Align's pricing and product mix, potentially altering its investment narrative and risk-reward profile. Investors are urged to consider this alongside the company's revenue guidance and analyst forecasts for future growth and profitability.
SG Americas Securities LLC Increases Stake in Align Technology, Inc. $ALGN
SG Americas Securities LLC significantly increased its holdings in Align Technology (NASDAQ:ALGN) by 183.4% in the fourth quarter, now owning 138,489 shares valued at $21.625 million. This follows strong Q4 earnings where Align Technology beat analyst estimates with EPS of $3.29 and revenue of $1.05 billion. Analyst sentiment is improving, with multiple firms raising price targets and the stock holding a "Moderate Buy" consensus rating.
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
C4 Therapeutics, Inc. (CCCC) has seen strong year-to-date performance, gaining 37.2%, significantly outperforming the Medical sector's average return of -5.9%. The company holds a Zacks Rank of #2 (Buy) and has had its full-year earnings consensus estimate revised 16.8% higher in the past quarter, indicating positive analyst sentiment. Another Medical stock, Align Technology (ALGN), also outperformed the sector with a 13.6% return year-to-date and also holds a Zacks Rank #2 (Buy).
THE COOPER Cyclically Adjusted PB Ratio: 2.20 — 50% Below
The Cooper Companies Inc's (COO) Cyclically Adjusted PB Ratio currently stands at 2.26, which is 48% below its 10-year median of 4.37. GuruFocus rates COO with a GF Score of 96/100 and a GF Value of $102.22, indicating it is significantly undervalued despite having two warning signs for investors. The company's Cyclically Adjusted Book per Share for January 2026 was $31.64, and its current share price is $71.43.
The Bull Case For Align Technology (ALGN) Could Change Following FTSE All-World Index Removal – Learn Why
Align Technology (ALGN) was removed from the FTSE All-World Index in March 2026, which may impact its shareholder base and liquidity. While this technical change doesn't alter immediate growth drivers, it could influence how institutional investors view the stock's risk-reward profile, particularly alongside existing pressures on pricing and product mix. The article discusses Align's investment narrative, financial forecasts, and encourages investors to conduct their own analysis given these evolving considerations.
Align Technology (ALGN) $4.0B 2025 revenue, board refreshment and 2026 proxy
Align Technology's 2026 Proxy Statement details its 2025 financial results, including $4.0 billion in net revenues, and outlines strategic priorities such as international expansion and AI-enabled treatment enhancements. The company is also proposing governance changes, including board refreshment and adjustments to executive compensation to better align with stockholder interests. Stockholders will vote on these proposals, as well as the election of ten directors and the ratification of the independent auditor, at the virtual annual meeting on May 20, 2026.
ALGN (Align Technology) Net Change in Cash : $51 Mil (TTM As of Dec. 2025)
Align Technology (ALGN) recorded a Net Change in Cash of $51 million for the trailing twelve months (TTM) ended December 2025, and $90 million for the quarter ended December 2025. GuruFocus assesses ALGN with a GF Score of 89/100 and a GF Value of $249.91, indicating it is significantly undervalued compared to its current price of $166.38, despite having six warning signs for investors. The article details the calculation of Net Change in Cash and provides historical data and comparisons for the company.
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know
Shares of Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell experienced declines in the afternoon session as major indices fell due to escalating uncertainty about the U.S.-Iran conflict and policy deadlines. The market's dislike for unpredictability, amplified fears of prolonged conflict, and rising oil prices contributed to a negative outlook reflected in consumer confidence. Despite the market downturn, such significant price drops are noted as potential buying opportunities for high-quality stocks.
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know
Several major stock indices, including the S&P 500 and Dow Jones Industrial Average, declined today due to escalating uncertainty surrounding the U.S.-Iran conflict and Trump administration policy deadlines, causing significant drops in various company shares. Specifically, Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell experienced notable share price decreases. The market's negative reaction to unpredictability was also reflected in a dip in consumer confidence, though such price drops can sometimes present buying opportunities for high-quality stocks.
Align Technology Inc. stock underperforms Friday when compared to competitors
Align Technology Inc. (ALGN) shares fell by 6.17% on Friday, closing at $166.38, in a generally poor trading session for the stock market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines of 1.67% and 1.73% respectively. This marks the second consecutive day of losses for Align Technology Inc. stock.
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell Shares Are Falling, What You Need To Know
Shares of Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell experienced significant drops due to market reactions to the escalating U.S.-Iran conflict and policy deadlines from the Trump administration, leading to increased uncertainty and a decline in consumer confidence. Align Technology, in particular, fell by 6.7%, though its shares have shown some volatility and a slight gain year-to-date. The article suggests that such market overreactions can present buying opportunities for high-quality stocks.
Reasons to Consider Including Cooper Companies Shares in Your Investment Portfolio Today
Cooper Companies (COO) is experiencing growth due to CooperVision's premium lenses and myopia management and CooperSurgical's women's health and fertility portfolio. Despite short-term challenges like Asia-Pacific weakness and geopolitical risks, the company maintains a strong competitive edge, boasts improving margins through efficiency, and benefits from a recovering fertility market. Analysts project increased revenues and EPS for fiscal 2026, with the stock currently holding a Zacks Rank #2 (Buy).
Reasons to Add Cooper Companies Stock to Your Portfolio Now
The Cooper Companies (COO) is recommended as a Zacks Rank #2 (Buy) stock due to its market share gains, premium product momentum in CooperVision, and strong margin expansion driven by operational efficiencies and AI adoption. CooperSurgical's growth is also supported by recovery trends in the fertility market. Despite challenges like Asia-Pacific weakness and geopolitical risks, the company's long-term opportunities are strong.
Reasons to Add Cooper Companies Stock to Your Portfolio Now
The Cooper Companies (COO) is positioned for growth due to the success of its CooperVision premium lens migration and MiSight's myopia management, alongside CooperSurgical's women's health portfolio. While facing near-term challenges like Asia-Pacific weakness and geopolitical risks affecting its fertility segment, the company shows strong long-term potential fueled by market share gains, operational efficiencies, and recovery in the fertility market. Analysts project a 5.5% revenue growth and 11.7% adjusted EPS improvement for fiscal 2026.
Riverbridge Partners LLC Sells 119,935 Shares of Align Technology, Inc. $ALGN
Riverbridge Partners LLC significantly reduced its stake in Align Technology (NASDAQ:ALGN) by selling 119,935 shares in Q4, now holding 0.10% of the company valued at $11.45 million. Concurrently, an EVP also sold a substantial portion of his shares. Despite this, Align Technology recently surpassed analyst expectations for earnings and revenue, maintaining a "Moderate Buy" analyst rating.
The Bull Case For Align Technology (ALGN) Could Change Following FTSE All-World Index Removal – Learn Why
Align Technology (ALGN) was recently removed from the FTSE All-World Index, which could impact its passive investment flows and liquidity profile by affecting how large institutional investors gain exposure to the company. While the exclusion doesn't alter Align's near-term drivers like case volumes and pricing pressures, it introduces a technical factor that intersects with these challenges. Investors should consider how this index change might influence the company's longer-term narrative, especially in light of its revenue guidance and pressure on profitability.
3D Systems Unlocks European Denture Market With Full EU MDR Clearance
3D Systems has achieved full EU MDR certification, allowing it to introduce its NextDent Jetted Denture Solution and other dental product lines into the European market. This certification is crucial for accessing the significant European denture market, which is comparable to or larger than the U.S. market. The move is expected to drive substantial revenue growth for 3D Systems, placing it in competition with other companies also seeking similar European certifications.
